Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
14 mars 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
13 mars 2018 16h35 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
13 mars 2018 07h00 HE
|
Melinta Therapeutics
Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI Acquired Infectious Disease Business from The Medicines Company on January 5, 2018 First Earnings Report as a Public...
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
08 mars 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics to Present at The Cowen and Company 38th Annual Health Care Conference
02 mars 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 02, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage pharmaceutical company developing and commercializing novel antibiotics to treat...
Melinta Therapeutics To Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
28 févr. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTI
27 févr. 2018 16h05 HE
|
Melinta Therapeutics
- VABOMERE demonstrated a greater numerical overall success rate vs piperacillin-tazobactam - VABOMERE safety profile comparable to piperacillin-tazobactam NEW HAVEN, Conn., Feb. 27, 2018 (GLOBE...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20 févr. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29 janv. 2018 07h00 HE
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Announces Initiation of Program for Radezolid in Patients with Bacterial Vaginosis
18 janv. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...